<DOC>
	<DOCNO>NCT01403636</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy SAR245409 determine objective response rate ( ORR ) patient 1 follow relapsed refractory lymphoma leukemia subtypes : mantle cell lymphoma ( MCL ) , follicular lymphoma ( FL ) , chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) , diffuse large B cell lymphoma ( DLBCL ) Secondary Objectives : - To assess duration response , progression free survival ( PFS ) , proportion patient PFS 6 month ( 24 week ) patient either MCL , FL , CLL/SLL DLBCL treat SAR245409 - To evaluate safety tolerability SAR245409 patient MCL , FL , CLL/SLL DLBCL - To characterize plasma pharmacokinetics ( PK ) SAR245409 patient MCL , FL , CLL/SLL DLBCL</brief_summary>
	<brief_title>A Study Investigational SAR245409 Patients With Certain Lymphoma Leukemia</brief_title>
	<detailed_description>There 21 day screen period follow 28 day cycle . Patients continue receive SAR245409 long clinical benefit study withdrawal criterion meet . The last posttreatment visit 30 day last dose IMP-related toxicity resolve deem irreversible , whichever later .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Inclusion criterion : Tissue archive fresh tumor sample A peripheral blood buffy coat sample require CLL/SLL . Patient mantle cell lymphoma ( MCL ) , follicular lymphoma ( FL ) , chronic lymphocytic leukemia ( CLL ) /SLL diffuse large B cell lymphoma Patient &gt; = 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 . Patients DLBCL ECOG &lt; = 1 Adequate white blood cell hemoglobin Good kidney liver function Fasting glucose &lt; 160 mg/dL No malignancy Use adequate birth control Exclusion criterion : Treatment cytotoxic chemotherapy , biologic agent , investigational therapy within 4 week , nitrosoureas mitomycin C within 6 week study enrollment Treatment smallmolecule kinase inhibitor within 2 week , 5 half life drug active metabolite ( whichever longer ) study enrollment Prior treatment PI3K , mTOR , Akt inhibitor . Prior treatment MCL temsirolimus permit patient enrolled country license indication . Radiation therapy within 2 week enrollment Autologous stem cell transplantation within 16 week enrollment Prior allogeneic transplantation except patient R/R DLBCL meet inclusion criterion Central nervous system ( CNS ) leptomeningeal involvement . Patients DLBCL may active CNS leptomeningeal involvement . Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( antiHCV ) serology Primary CNS lymphoma Primary mediastinal Blymphoma The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>